Denali Therapeutics
DNLI44
$15.49arrow_drop_up4.03%$0.60
DNLI44
$15.49
arrow_drop_up4.03%| Key Stats | |
|---|---|
| Open | $14.87 |
| Prev. Close | $14.87 |
| EPS | -2.57 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 14.39 | 15.67 |
| 52 Week Range | 11.98 | 33.29 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | -2.57 |
| Fundamentals | |
|---|---|
| Gross Profit | - |
| Payout Ratio | - |
| Industry average yield | 2.87% |
| Last Dividend pay date | - |
| Dividend per share | - |
| Dividend yield forecast | - |
Stock Analysis
Technicals
Summarizing what the indicators are suggesting.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Analyst rating
An aggregate view of professional's ratings.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Stock Performance
DNLI-
US Healthcare Sector-
US Market-
check_circle
DNLI / Market
DNLI exceeded the US Market which returned 1.29% over the last twenty four hours.check_circle
DNLI / Healthcare Sector
DNLI exceeded the US Healthcare sector which returned 3.64% over the last twenty four hours.Denali Therapeutics (DNLI) Statistics
Keep an eye on Denali Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
How has Denali Therapeutics (DNLI) stock's performance compared to its sector and the market over the past year?
Over the past year, Denali Therapeutics (DNLI) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.41%, Denali Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 35.60%, it has fallen short of the market average. This comparison highlights Denali Therapeutics 's performance relative to both its sector and the overall market over the last year.
help
What is the PE ratio of Denali Therapeutics (DNLI) stock?
The PE ratio for Denali Therapeutics (DNLI) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help
What is the EPS of Denali Therapeutics (DNLI) stock?
The Earnings Per Share (EPS) for Denali Therapeutics (DNLI), calculated on a diluted basis, is -$2.57. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help
What is the operating margin of Denali Therapeutics (DNLI) stock?
The operating margin for Denali Therapeutics (DNLI) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help
What is the EBITDA of Denali Therapeutics (DNLI) stock?
The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Denali Therapeutics (DNLI) is -$492.89M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help
How much debt does Denali Therapeutics (DNLI) have?
Denali Therapeutics (DNLI) has a total debt of $42.29M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$126.25M.